Clinical Trial Finder

Inclusion Criteria:

• - Provision of signed and dated informed consent form.

• - Stated willingness to comply with all study procedures and availability for the duration of the study.

• - Histologically confirmed salivary duct carcinoma and stage III or IVa or IVb according to AJCC Cancer Staging Manual Eighth Edition.

• - Completed SDC surgery, and adjuvant radiotherapy is planned or ongoing or has completed.

• - Androgen receptor (AR) positive.

• - White blood cell (WBC) ≥ 3.0 x 10^9/L, Neutrophil count≥ 1.5 x 10^9/L, Platelet count (PLT) ≥ 75 x 10^9/L, Haemoglobin (Hb) ≥ 90 g/L.

• - Serum creatinine (Cr) < 1.5 x upper limit of normal(ULN) or creatinine clearance ≥ 50 ml/min.

• - Total bilirubin (TBIL) < 1.5 x ULN, AST< 2.5 x ULN, and ALT< 2.5 x ULN.

• - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2, and ability to take oral medication.

• - For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 1 year after the end of study intervention administration.

• - For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.

Exclusion Criteria:

• - Received prior anti-AR pathway therapy.

• - Treatment with another investigational drug or chemotherapy within 6 months.

• - History of hypothalamus or pituitary dysfunction.

• - History of seizure.

• - Clinically uncontrolled diseases, such as septic shock, uncontrolled hypertension, unstable angina, New York Heart Association (NYHA) class III or IV heart disease, clinically unstable arrhythmia, myocardial infarction (in the past 6 months) - Previous cancer except skin cancer rather than malignant melanoma or any cancer curatively treated > 5 years prior to study entry.

- Pregnancy or lactation

Arms

Experimental: Rezvilutamide plus LHRHa

Participants will receive rezvilutamide in combination with a LHRHa for up to 2 years.

Interventions

Drug: - Rezvilutamide

Rezvilutamide 240 mg (3*80mg tablets) will be administered orally once daily with or without food.

Drug: - Leuprolide Acetate

The dose and frequency of administration will be consistent with the prescribing information in prostate cancer patients.